Drugs Made in America Acquisition Corp. 8-K Filing Summary

This filing reports on an extraordinary general meeting of shareholders held by Drugs Made in America Acquisition Corp. on April 27, 2026. The shareholders approved an extension proposal to amend the company's governing documents to extend the deadline for consummating a business combination. The combination period is extended up to twelve times, one month at a time, from April 29, 2026, to April 29, 2027. This extension is contingent upon the company's sponsor depositing funds into the Trust Account, with the amount being the lesser of $300,000 or $0.04 per non-redeemed public share for each one-month extension. The company also reported that holders of 9,440,230 ordinary shares exercised their right to redeem their shares, resulting in approximately $99,336,016.67 being removed from the Trust Account. The Board of Directors has approved an initial one-month extension to May 29, 2026.